ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Nicholas G. Smedira
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smedira, N. G.
Right arrow Articles by Gillinov, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smedira, N. G.
Right arrow Articles by Gillinov, A. M.
Related Collections
Right arrow Electrophysiology - arrhythmias

Ann Thorac Surg 2006;81:76-77
© 2006 The Society of Thoracic Surgeons

Original article: Cardiovascular

Invited commentary

Nicholas G. Smedira, MD, A. Marc Gillinov, MD

Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, 9500 Euclid Ave, Desk F25, Cleveland, OH 44195

(Email: smedirn@ccf.org; gillinom@ccf.org).

The first 20% of the full text of this article appears below.

To compete with percutaneous endocardial ablation techniques for the treatment of atrial fibrillation (AF), several surgical epicardial approaches have been introduced into clinical practice, and additional techniques are currently under development. These surgical epicardial procedures make use of alternate energy sources and minimally invasive access to produce atrial lesions to ablate AF. There is a plethora of new ablation devices designed specifically to facilitate these minimally invasive procedures. Gaynor and colleagues [1] note that these devices must "be able to produce transmural lesions on the arrested and beating heart safely without producing collateral damage to vital structures. This requires the development of dose response curves on living tissue." To their credit, they have developed a . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2006 by The Society of Thoracic Surgeons.